We demonstrate the feasibility of using flow cytometry (FC) In addition to CD30 and CD15, a variety of other antigens are expressed on HRS cells at high levels and may be useful in identifying these cells in CHL. 1,4-6 CD40 is a member of the tumor necrosis factor receptor family 13, 14 and is expressed on a number of cell types, including most B cells. 15 Through its interaction with CD40 ligand, CD40 serves as a signal for T-cell activation of B cells, resulting in immunoglobulin class switching. 15 HRS cells also express CD40 [16] [17] [18] [19] ; 1 study showed strong CD40 expression in all 185 cases of CHL examined by immunohistochemical analysis. 16, 17 CD95 (Fas), also a member of the tumor necrosis factor receptor family, initiates apoptosis when crosslinked by its binding partner Fas ligand (CD95L), is expressed by germinal center B cells, and is involved in selective deletion of B cells with low-affinity antibody. 20 CD95 is expressed on HRS cells in the vast majority (>90%) of CHL cases. 21-24 CD71 (transferrin receptor) is expressed on a wide variety of proliferating cells, 25 including 85% of CHL cases. 8 CD86 (with CD80) is a costimulatory molecule on B cells that contributes to T-cell activation by binding
A b s t r a c t

We demonstrate the feasibility of using flow cytometry (FC) to identify the Hodgkin and ReedSternberg (HRS) cells of classical Hodgkin lymphoma (CHL). Initial flow cytometric studies of the HRS cell line L1236 demonstrated potentially useful antigens for identifying HRS cells. L1236 cells spontaneously bound normal T cells, analogous to the T-cell rosetting of HRS cells seen in tissue sections of CHL, but these interactions could be blocked by using a cocktail of unlabeled antibodies to 4 adhesion molecules. Among 27 lymph nodes involved by CHL, FC enabled HRS cells to be identified in 89%, whereas none of 29 non-CHL neoplasms or 23 reactive lymph nodes demonstrated HRS populations. Of the CHL cases, 82% demonstrated interactions between HRS cells and T cells that could be disrupted with blocking antibodies. Flow cytometric cell sorting experiments demonstrated typical HRS cytomorphologic features among the purified cells. FC may offer an alternative to immunohistochemical analysis in confirming the diagnosis of CHL in certain cases, and, through cell sorting, it provides a means of rapidly isolating pure HRS cells.
Traditionally, the diagnosis of classical Hodgkin lymphoma (CHL) has required the morphologic identification of neoplastic Hodgkin and Reed-Sternberg cells (collectively referred to as HRS cells) in a characteristic background of reactive lymphocytes, histiocytes, plasma cells, and eosinophils. [1] [2] [3] This diagnosis usually is confirmed by immunocytochemical detection of CD15 and CD30 and the absence of expression of CD20, CD3, and CD45 by the HRS cells. [3] [4] [5] [6] [7] One unique characteristic of this disease is the ringing ("rosetting") of the HRS cells by T cells, 3, [8] [9] [10] [11] [12] a diagnostically useful phenomenon.
In addition to CD30 and CD15, a variety of other antigens are expressed on HRS cells at high levels and may be useful in identifying these cells in CHL. 1, [4] [5] [6] CD40 is a member of the tumor necrosis factor receptor family 13, 14 and is expressed on a number of cell types, including most B cells. 15 Through its interaction with CD40 ligand, CD40 serves as a signal for T-cell activation of B cells, resulting in immunoglobulin class switching. 15 HRS cells also express CD40 [16] [17] [18] [19] ; 1 study showed strong CD40 expression in all 185 cases of CHL examined by immunohistochemical analysis. 16, 17 CD95 (Fas), also a member of the tumor necrosis factor receptor family, initiates apoptosis when crosslinked by its binding partner Fas ligand (CD95L), is expressed by germinal center B cells, and is involved in selective deletion of B cells with low-affinity antibody. 20 CD95 is expressed on HRS cells in the vast majority (>90%) of CHL cases. [21] [22] [23] [24] CD71 (transferrin receptor) is expressed on a wide variety of proliferating cells, 25 including 85% of CHL cases. 8 CD86 (with CD80) is a costimulatory molecule on B cells that contributes to T-cell activation by binding CD28 on the T-cell surface. [26] [27] [28] [29] [30] CD86 shows near-ubiquitous expression on HRS cells. 31, 32 Finally, HLA-DR is found on antigen-presenting cells, activated T cells, and virtually all B cells. 33 Multiple studies have demonstrated HLA-DR expression on HRS cells. 8, 34, 35 Although flow cytometry (FC) is useful for the diagnosis of most hematopoietic neoplasms, attempts to identify the neoplastic HRS cells of CHL by FC have been largely unsuccessful. Most flow cytometric studies of CHL have examined changes in the reactive T-cell populations, such as the characteristic increase in the CD4/CD8 ratio, 36 rather than characterizing the HRS cells. Recently, Ravoet and coworkers 37 identified putative HRS cell populations by using a 3-color FC assay. However, whether this population truly represented HRS cells, as opposed to another cell population such as macrophages, was not confirmed by a second, independent technique. Consequently, definitive identification of HRS cells has not been demonstrated in clinical specimens.
The rosetting of T cells around HRS cells is a wellknown phenomenon described in the 1970s. [8] [9] [10] [11] [12] By using tissue cultures from lymph nodes involved by CHL, Stuart et al 12 identified a dynamic interaction between lymphocytes and HRS cells, in which small lymphocytes were observed to attach and release from HRS cells, occasionally resulting in "morulae" (HRS cells buried in a shell of lymphocytes). Subsequently, Sanders and coworkers 38 demonstrated that this rosetting is due to binding between molecules on the surface of the HRS cells (CD54 and CD58) with their ligands on T cells (LFA-1 [lymphocyte function-associated antigen-1] and CD2, respectively), and that monoclonal antibodies to these macromolecules could specifically disrupt the interactions between T cells and HRS cells. Specifically, a combination of monoclonal antibodies to LFA-1 and CD58 was particularly effective at abrogating this interaction. 38 We hypothesized that the HRS cell-T cell rosettes in CHL have contributed to the historic difficulty in identifying HRS cells by FC, by causing HRS cells to have a composite immunophenotype (CD15+/CD30+/CD40+/CD45+/CD71+/CD95+/HLA-DR+/CD3+/CD20-/CD19-) due to contributions by the HRS cell and the surrounding T cells. We further hypothesized that using specific monoclonal antibodies to disrupt HRS cell-T cell interactions could generate "naked" HRS cells that then could be shown to have the expected immunophenotype by FC (CD15+/CD30+/CD40+/CD45-/ CD71+/CD95+/HLA-DR+/CD3-/CD20-/CD19-). In this article, we describe a novel flow cytometric assay that directly identifies HRS cells in lymph nodes with high sensitivity and specificity. This method holds the promise of diagnosing CHL by FC. In addition, application of this technique to cell sorting provides rapid purification of HRS cells.
Materials and Methods
Cells and Unlabeled Antibodies
The L1236 Hodgkin cell line, from Deutsche Sammlung für Mikroorgansimen und Zellkulturen (Braunschweig, Germany), was cultured in RPMI 1640 (GIBCO BRL, Invitrogen, Carlsbad, CA) supplemented with 8% fetal calf serum, 100 U/mL of penicillin/streptomycin, and 2 mmol/L of L-glutamine. Unlabeled antibodies were as follows: anti-CD58 (TS2/9, Endogen, Woburn, MA), anti-CD54 (84H10, Serotec, Oxford, England), anti-CD2 (RPA-2.10, Becton Dickinson, San Jose, CA), anti-LFA-1 (MHM23, DAKO, Carpinteria, CA), and anti-CD40 (MAB89, Beckman Coulter, Hialeah, FL).
Fluorescently Labeled Antibodies and Isotype Controls
For all experiments, FC was performed on a modified 4-laser, 10-color Becton Dickinson LSRII flow cytometer (same flow cytometer used for clinical cases at the University of Washington Medical Center, Seattle) using the following laser-fluorochrome combinations: (1) 405-nm violet laser (1 color), Pacific blue (PB) or DAPI (4',6-diamidino-2-phenylindole); (2) 488-nm blue laser (5 colors), fluorescein isothiocyanate (FITC), phycoerythrin (PE), PE-Texas red (ECD/PE-TR), PE-cyanine (Cy)-5 (PE-Cy5), PE-Cy5.5, peridinin chlorophyll protein (PerCP)-Cy5.5, and PE-Cy7; (3) 594-nm yellow laser (1 color), AlexaFluor 594 (A594); and (4) 633-nm red laser (3 colors), allophycocyanin (APC), APCAlexaFluor 700 (APC-A700), and APC-Cy7.
The specific fluorescently labeled antibodies used in this study were obtained from Beckman Coulter, DAKO, Caltag (Burlingame, CA), and Becton Dickinson. Antibodies (including clone designation) from Becton Dickinson included the following: CD2-FITC (55.2), CD3-FITC/PE (SK7), CD5-FITC (LHF12), CD10-PE (HI10a), CD13-PE (L138), CD15-FITC (MMA), CD15-APC (H198), CD19-PE/A594 (SJ25C1), CD20-FITC/PE/APC (L27), CD23-PE (EBVCS-5), CD30-PE (Ber-H83), CD33-FITC/PerCPCy5.5/PE-Cy7 (P67.6), CD34-PE (8G12), CD45-APC-Cy7/PB (2D1), CD57-BD (HNK-1), CD58-PE (L306.4), CD68-PE (Y1/82A), CD86-PE (FUN-1), CD95-APC (DX2), HLA-DR-FITC (L243), κ light chains-FITC (TBC-8-2), and λ light chains-PE (1-155-2). Antibodies from Beckman Coulter included the following: CD3-ECD/PE-Cy7 (UCHT1), CD4-FITC (SFCI12T4D11), CD5-APC-Cy7 (BL1a), CD8-FITC (SFCI21Thy2D3), CD14-ECD (RMO52), CD20-PE-Cy7 (B939), CD22-FITC (S-HCL-1), CD27-PE (1A4CD27), CD28-PE (28.2), CD38-PE (T16), CD40-PE/PE-Cy5.5 (MAB89), CD43-FITC (DFT1), CD45-PE/ECD (J33), CD64-FITC/PE (22) , CD71-FITC/APC-A700 (YDJ.1.2.2), HLA-ABC-FITC (B9.12.1), and HLA-DR-ECD (Immu-357).
Antibodies from Caltag included CD24-FITC (SN3) and CD54-PE (MEM-111). Antibodies from DAKO included the following: CD30-FITC (BerH2), CD79b (SN8), CD95-FITC (DX2), and CD117-PE (104D2). Appropriate isotype controls also were used.
Surface and Cytoplasmic Cell Immunophenotyping of the Hodgkin Cell Line, L1236
Unless otherwise stated, all incubations were performed at room temperature in the dark. For surface immunophenotyping, 20,000 to 100,000 L1236 cells were incubated with titered, fluorescently labeled antibody for 15 minutes in approximately 100 µL of RPMI. Cells suspensions were lysed and fixed with 0.25% paraformaldehyde and 0.15 mol/L of ammonium chloride, pH 4.8, for 15 minutes, washed with 3 mL of phosphate-buffered saline (PBS)-bovine serum albumin-azide, and incubated with 0.1 mL of 1:10 DAPI (to exclude nonviable cells) in PBS before analysis. For combined cell surface and cytoplasmic immunophenotyping, cells were incubated for 15 minutes with surface-reactive labeled antibodies, washed twice, incubated for 15 minutes with 100 µL of Caltag Fix and Perm reagent "A," and washed twice. After the addition of 100 µL of Caltag Fix and Perm reagent "B," cells were washed twice, incubated for 30 minutes with antibodies to cytoplasmic antigens, washed, and analyzed on the cytometer.
L1236 Cells and Normal Lymphocyte Binding Experiments
L1236 cells (20,000-60,000) and normal lymph node cells (2 to 6 million, with normal B-and T-cell immunophenotypes by FC) were mixed in 0.5 to 1.5 mL of RPMI and incubated on ice for 1 hour. Separate control tubes, containing only L1236 cells or normal lymphocytes, were similarly treated. Aliquots (100 µL) of the 3 tubes then were immunophenotyped as in the preceding description.
Unlabeled Antibodies Block the Interaction of L1236 Cells and T Cells or HRS Cells and T Cells in Lymph Nodes Involved by CHL
Normal lymph node cells combined with L1236 cells (7 million and 70,000, respectively; reaction tube A), normal lymph node cells alone (7 million; reaction tube B), or L1236 cells alone (70,000; reaction tube C) each were placed in 1.25 mL of RPMI and incubated on ice for 1 hour. From these 3 tubes, a total of 9 FC tubes were prepared (7 from reaction tube A, 1 from tube B, and 1 from tube C). Reaction tube mixture A was divided into aliquots (160 µL) and incubated with individual blocking antibodies to CD40 (4 µg), CD2 (5 µg), CD58 (10 µg), CD54 (10 µg), or LFA-1 (12 µg), with a combination of all 5 blocking antibodies, or with no blocking antibody, on ice for 1 hour. Similar 160-µL aliquots were prepared from reaction mixtures B and C (no blocking antibodies added).
From CHL-involved lymph nodes, approximately 250,000 to 300,000 cells were incubated in 100 µL of RPMI for 1 hour at room temperature with the following: (1) 1 of the 5 unlabeled antibodies (listed in the preceding paragraph); (2) all 5 unlabeled antibodies together; or (3) no unlabeled antibody. All samples then were stained with labeled antibodies and analyzed as in the preceding description.
Rosettes were defined as events with an HRS immunophenotype that have apparent expression of T-cell antigens (CD3 or CD5) and lose expression of T-cell antigens (and some CD45 expression) when first preincubated with blocking antibody cocktail. The efficiency of rosette blockage by the unlabeled antibodies was calculated as 100% minus the following quotient: percentage of L1236 or HRS cells bound in a given tube divided by the percentage of L1236 cells bound in the mixture without blocking antibody.
Preparation of Lymph Node Suspensions
Lymph node suspensions were prepared in a manner identical to that used for routine clinical immunophenotyping of tissues in our laboratory. Briefly, tissue was finely minced in 3 to 5 mL of RPMI using a scalpel. The homogenate then was filtered (through a 40-µm filter), centrifuged (550g for 10 minutes), washed with PBS, and resuspended in 0.5 mL of RPMI.
Clinical Specimen Selection and Flow Cytometry
This study was conducted with the approval of the University of Washington Human Subjects Review Committee (96-2538-V/E22). We identified 30 fresh lymph nodes, obtained from August 2004 to June 2005 in the University of Washington Hematopathology Laboratory (UWHL) for flow cytometric evaluation to rule out lymphoma, that showed the cellular background of CHL with or without putative HRS cells on cytocentrifuge preparations. Three specimens were excluded from the study after FC was performed because these studies suggested the specimens were too degenerated to yield meaningful data. The remaining 27 lymph nodes (numbered cases 1-27) subsequently were shown to be involved by CHL by histologic examination and immunohistochemical analysis after the flow cytometric diagnosis was made. The control tissue samples included 23 nonneoplastic lymph nodes received for flow cytometric evaluation (20 with reactive lymphoid hyperplasia of various types and 3 with granulomatous inflammation) and 29 non-CHL large cell neoplasms received for flow cytometric evaluation ❚Table 1❚. Diagnoses for the control tissue samples were determined by a combination of histologic examination, conventional FC at the UWHL, and immunohistochemical analysis. Putative HRS cells were identified by the following: (1) expression of HLA-DR, CD15 (surface and cytoplasmic), CD30 (surface and cytoplasmic), CD40, CD71, CD86, and CD95; (2) increased forward scatter (FS) and side scatter (SS) compared with normal lymphocytes; and (3) absence of T-cell (CD2, CD3, and CD5), B-cell (CD19 and CD20), and macrophage-associated (CD14, CD33, CD64, and cytoplasmic CD68) antigens. Owing to HRS-T cell interactions, a "hybrid" HRS-T-cell immunophenotype (CD3+/ CD15+/CD19-/CD20-/CD30+/CD40+/CD45+/CD71+/ CD86+/CD95+/HLA-DR+) was expected in the absence of blocking antibody, whereas the typical HRS cell immunophenotype(CD3-/CD15+/CD19-/CD20-/CD30+/CD40+/ CD45-/CD71+/CD86+/CD95+/HLA-DR+) was expected in the presence of blocking antibodies.
Absolute requirements for identifying a high FS/high SS population as HRS cells included the following: (1) events had to form a discrete cluster in multidimensional space and (2) have coexpression CD30 3,39,40 and CD40, 16, 17 (present on HRS cells of virtually all cases of CHL in tissue sections) in cases in which these antigens were examined by FC. Expression of CD15 was not required to define HRS cells because only 75% to 85% of CHL cases express this antigen in tissue sections. 3, [40] [41] [42] Other HRS-associated antigens (CD71, CD86, CD95, and HLA-DR), although useful in the identification of HRS cell populations, were considered less sensitive and, therefore, were not required to define HRS cell populations. Likewise, low-to-negative CD45 (blocked state) and the absence of bright CD3 (blocked state), CD19, and CD20 were considered useful but not required. For the initial cases, because the expression of CD30, CD40, and CD95 was not examined, cases were evaluated using the other measured antigens. Although cases judged to be diagnostic demonstrated a discrete population with an appropriate immunophenotype, suspicious cases had similar immunophenotypes but fewer events and/or decreased FS (suggesting degeneration), resulting in a less distinct population. Indeterminate cases had some (but not all) immunophenotypic characteristics of CHL and did not form a discrete population. Negative cases had essentially no events meeting the aforementioned criteria.
Expression of CD40, CD86, and CD95 by HRS in Paraffin Sections
Four-micrometer, formalin-fixed sections were deparaffinized and subjected to the following pretreatments: 10 minutes in Protease-24 (CD40), 15 minutes in pH 8.0-buffered EDTA in a pressure cooker (CD86), or 10 minutes in pH 10-buffered tris(hydroxymethyl)aminomethane (CD95). After endogenous peroxidase was blocked with 0.5% hydrogen peroxide in methanol, the following primary antibodies were applied to the sections: CD40 (MAB89, BC), CD86 (2331, BD), and CD95 (FAS, Novocastra, Newcastle upon Tyne, England). Immunostaining was detected using a horseradish peroxidase-conjugated detection system.
Cell Sorting of Lymph Nodes Involved by CHL
Cells from four CHL cases judged to be diagnostic for CHL were stained with CD15-FITC, CD86-PE, CD45-ECD, CD40-PE-Cy5.5 (case 5), CD15-FITC, CD86-PE, CD45-ECD 
Alexa, AlexaFluor; APC, allophycocyanin; Cy, cyanine; DAPI, 4',6-diamidino-2-phenylindole; ECD, PE-Texas red; FITC, fluorescein isothiocyanate; PB, Pacific blue; PE, phycoerythrin. * Typically the first tube is unblocked and the second tube is blocked with an antibody cocktail (see text for details).
(case 6), CD15-FITC, CD30-PE, CD40-PE-Cy5. 
Results
Flow Cytometry Studies of L1236 Cells
The expression of a number of B and T cell-associated antigens, adhesion molecules, and other antigens was evaluated in the CHL cell line L1236 to identify antigens useful in the identification of HRS cells in lymph nodes by FC ❚Image 1B❚. As shown previously, 43 these cells demonstrated a flow cytometric immunophenotype that is nearly identical to that typically seen on immunohistochemical evaluation of paraffin sections of CHL ❚Table 3❚. L1236 cells lacked additional B cell-associated antigens, including CD19, CD22, and CD23, but brightly expressed HLA-DR, CD40, and CD86. Additional antigens expressed at high levels by these cells included CD71, CD54, CD58, and CD95. The T cell-associated antigens, including CD2, CD3, CD4, CD5, and CD8 were not detected, whereas CD45 was expressed at intermediate levels.
T Cells From Normal Lymph Nodes Spontaneously Bind to L1236 Cells
To evaluate HRS-T cell interactions, a model system was used in which L1236 cells were mixed with lymphocytes from disaggregated normal lymph nodes and tonsils. 38 These normal tissues were composed primarily of CD20+ B cells, CD3+ T cells, and essentially no cells coexpressing CD71 and CD15 ❚Image 1A❚. In contrast, L1236 cells were CD71+ and CD15+ and CD3-and CD20-(Image 1B). When L1236 cells and normal lymphoid cells were mixed (ratio, 1:100), the majority of CD71+/CD15+ L1236 cells also appeared to express CD3 and show increased FS, suggesting the presence of HRS-T cell aggregates ❚Image 1C❚. The small subset of the high FS/CD71+/CD15+ events not expressing CD3 likely represents naked (unligated) L1236 cells.
A Mixture of Unlabeled Monoclonal Antibodies Specifically Inhibits L1236-T Cell Binding
The L1236 cell-normal lymphocyte model system was used to study the ability of single, unlabeled antibodies or a cocktail of antibodies to inhibit L1236-T cell interactions. When L1236 cells were mixed with normal lymph node cells in a ratio of 1:100, 2 subsets of L1236 cells were present, as indicated in ❚Image 2A❚: one expressing CD5 and bright CD45 (oblique arrow), and a second with lower level CD45 and no CD5 (horizontal arrow), representing putative L1236-T cell aggregates and naked L1236 cells, respectively. Individual antibodies to CD2, LFA-1, CD40, CD54, and CD58 varied in their abilities to block L1236-T cell interactions, with the anti-CD2 and anti-CD58 antibodies being the most effective ❚Image 2E❚ and ❚Image 2F❚ (each antibody competing ~76% of bound T cells competed off the L1236 cells) and the anti-CD40 antibody being the least effective ❚Image 2B❚ (27.1% of T cells competed off). Anti-LFA-1 ❚Image 2D❚ (46.1% of T cells competed off) and anti-CD54 ❚Image 2C❚ (37.9% of T cells competed off) were of intermediate ability to disrupt Tcell-L1236 interactions. It is important to note that a cocktail of all 5 antibodies completely blocked the interaction of L1236 cells with T cells ❚Image 2G❚, causing the level of CD45 expression to return to that of L1236 cells alone and eliminating all concurrent CD5 expression. ❚Image 2H❚ and ❚Image 2I❚ show the expected immunophenotypes of normal lymphocytes and L1236 cells (alone), respectively.
Flow Cytometric Studies of Lymph Nodes Involved by CHL, Other Large Cell Neoplasms, and Benign Processes
Of the 27 lymph nodes (numbered 1-27) subsequently confirmed to have CHL by morphologic examination, all but 3 were judged (by 2 reviewers, J.R.F. and B.L.W.) to be suspicious of (6 cases) or diagnostic of (18 cases) CHL by FC ❚Image 3❚ and ❚Table 4❚. For the 6 suspicious cases and 18 diagnostic cases, the mean ages of patients were 43.5 and 51.7 years and the male/female ratio was 5 to 1 and 3.5 to 1, respectively.
The 18 cases considered diagnostic of CHL by FC demonstrated a number of common immunophenotypic features (Table 4 ). In addition to the required coexpression of CD30 and CD40 (in cases in which these antigens were examined), surface and/or cytoplasmic CD15 was detected in 16 (89%) of 18 cases, CD20 expression in 6 (35%) of 17 cases, and CD19 in 5 (29%) of 17 cases. When expressed by HRS cells, CD20 and CD19 typically were present at low levels. Although 14 of 17 cases evaluated showed rosette formation by FC, CD3 was lost from the HRS cells by the blocking antibody cocktail in 79% of these cases (data not shown).
FC identified some level of CD45 expression (relative to the corresponding isotype-matched control) on HRS cells in [NLPHL]) demonstrated a population suggestive of HRS cells ❚Image 4❚. In these control cases, the gating strategy was identical to that in the CHL cases, such that very high FS events (aggregates) were incorporated into the analysis to ensure inclusion of events that immunophenotypically could resemble HRS-T cell rosettes. In a few of these control cases, rare events with increased SS and expression of CD40 equal to or greater than the smaller B cells were identified, but these rare events typically lacked expression of CD71, CD95, CD15, and CD30 and/or did not represent a discrete population, arguing against these events representing HRS cells.
Immunohistochemical Confirmation of CD40, CD86, and CD95 Expression by HRS Cells in Tissue Sections of CHL Cases
It is important to note that with the exception of CD45 expression, there was high concordance between the expression of antigen by FC and immunohistochemical analysis (examples shown in Image 3). Paraffin sections from 6 CHL cases in which FC identified an HRS cell population were stained with antibodies to CD40, CD86, and CD95 to confirm the expression of these antigens previously identified by FC ❚Image 5❚. All 6 cases demonstrated at least partial to uniform strong expression of CD40, CD86, and CD95 in tissue sections (data not shown). CHL, NOS, classical Hodgkin lymphoma, not otherwise specified; MCHL, mixed cellularity Hodgkin lymphoma; NSHL, nodular sclerosis Hodgkin lymphoma. * The intensity of each antigen (surface or surface and cytoplasm for CD15 and CD30) for each case was measured above the background level for each fluorophore and scored as negative (0), dim (1), intermediate (2) , or bright in intensity (3). For CD3 and CD45, antigen intensity is described in the blocked state. † See the "Materials and Methods" section for definitions of the flow cytometric result subgroups. ‡ One negative case was a fine-needle aspiration specimen described morphologically as suspicious for CHL; a subsequent biopsy result was positive morphologically for CHL.
We were not able to definitively describe or evaluate the immunophenotype for the indeterminate/negative group.
Contribution of Unlabeled Antibodies in Blocking the Interaction of HRS Cells and T Cells in a Lymph Node
Involved by CHL Similar to the result in the L1236-T cell model system, blocking antibodies inhibited the HRS cell-T cell interactions in cell suspensions from lymph nodes involved by CHL. In this experiment, HRS cells in the lymph node suspension (case 6) were identified (as in the L1236-T cell model system) by their bright expression of CD15, CD71, and CD95; lack of expression of CD19; large size (high FS); and increased SS ❚Image cocktail of all 5 antibodies resulted in near-complete abrogation of the T cell-HRS cell interaction ❚Image 2P❚. Rosette disruption is specific, as a mixture of unlabeled antibodies to CD40L (binding partner of CD40) and CD28 (binding partner of CD86) had minimal to no effect on T cell-HRS cell interactions (data not shown).
Cell Sorting Experiments
To confirm that the populations identified by FC indeed represent HRS cells and to examine the usefulness of cell sorting as a possible preparative method for HRS cells, the cell suspensions from 4 CHL cases (5 sorting experiments) were sorted using antibodies to CD45 and brightly expressed antigens. Two cases were sorted in the absence (cases 19 and 26) ❚Image 6D❚ and ❚Image 6E❚, respectively, 1 in the presence (case 5) ❚Image 6C❚, and 1 in the presence ❚Image 6B❚ and absence ❚Image 6A❚ of blocking antibodies (case 6). Representative photomicrographs of cytocentrifuge preparations of the sorted HRS cell populations confirm that the sorted cells have the morphologic features of HRS cells. As shown in Image 6 from a single CHL case (case 6), sorting in the absence (Image 6A) and presence (Image 6B) of blocking cocktail confirmed that HRS-T cell rosettes can be detected by FC (Image 6A) and that the antibody cocktail can disrupt these rosettes (Image 6B). Case 19 was sorted in the absence of blocking antibody cocktail, demonstrating numerous T cells bound to HRS cells. The percentages of HRS cells collected and purities for the 5 cell sorting experiments are given in ❚Table 5❚.
Discussion
To our knowledge, this represents the first report of a flow cytometric assay that reliably identifies the malignant cells of CHL. That the population identified is a bona fide HRS cell population is supported by the following evidence: (1) The flow cytometric immunophenotype of HRS cells from clinical cases is very similar to that described in the literature. 3 can be specifically inhibited by a cocktail of blocking antibodies, phenomena well described in the literature. 38 In our series, 89% of cases (24/27) subsequently confirmed to represent CHL by morphologic examination were judged to be suspicious for or diagnostic of CHL by FC. Many of the cases classified as suspicious (instead of diagnostic) likely were because of the relatively small number of neoplastic cells remaining in the residual clinical material available for study owing to degeneration or sample limitations, a factor that would be greatly improved by more timely evaluation as would occur in the diagnostic setting. In particular, because HRS cells are highly proliferative, 44 selective death of the HRS cells might decrease the ratio of HRS cells to reactive lymphocytes in lymph nodes not processed immediately for study, a conclusion supported by anecdotal evidence.
Before being excluded from the study owing to specimen degeneration (1 of 3 cases excluded for this reason; see the "Materials and Methods" section), 1 morphologically proven CHL case initially was evaluated as "indeterminate" for CHL by FC. When the patient subsequently experienced a relapse, FC and morphologic examination of this lymph node were diagnostic for CHL (this subsequent case is not included in the present study). Because HRS cell immunophenotypes do not change significantly with time 45 and the initial and relapse specimens had similar morphologic features, the inability to detect an HRS population in the initial case very likely was because of specimen degeneration and lack of viable HRS cells. In addition, the immunophenotypes of the putative HRS cells in suspicious cases usually conform very closely to the immunophenotypes identified by immunohistochemical analysis.
No nonneoplastic (reactive) lymph nodes or large cell neoplasms (non-CHL) demonstrated a discrete HRS cell-like population by FC; consequently, these cases could be distinguished reliably from CHL by FC. It is important to note that because FC was performed before the morphologic diagnosis was made, the flow cytometric analysis was not biased by antecedent knowledge of the diagnosis. Although these results suggest this method may have a valuable role in the clinical diagnosis of CHL, evaluation of a larger series of unselected cases would be required to assess the true sensitivity and specificity of this technique.
Three diseases that commonly appear in the differential diagnosis of CHL-CD30+ T-cell malignant neoplasms, TCRLBCL, and NLPHL-deserve further discussion. Among the CD30+ T-cell malignant neoplasms, although there were no cases of anaplastic large cell lymphoma (ALCL) in our study, the 1 CD30+ peripheral T-cell lymphoma examined did not express CD40 or HLA-DR, findings excluding CHL as a possible diagnosis. Moreover, in tissue sections, CD40 has been shown to be present in a minority, if any, neoplastic cells in ALCL and, when present, is expressed less intensely than by the HRS cells of CHL. 16, 46 Likewise, rosetting of T cells would not be expected in ALCL, in contrast with CHL.
The bright expression of CD20 may be useful in differentiating TCRLBCL from CHL by FC. Although the 1 case of TCRLBCL in our study demonstrated some CD30 and relatively bright CD95, the uniformly strong CD20 on all the neoplastic cells in this case strongly argued against the diagnosis of CHL. Similarly, neither of the 2 cases of morphologically confirmed NLPHL in the non-CHL malignancy control group demonstrated a CHL immunophenotype by FC. Although clearly demonstrating promise, further flow cytometric studies comparing the immunophenotypes of ALCL, TCRLBCL, and NLPHL with CHL are required before the true usefulness of this method for distinguishing these entities can be determined.
Analysis of the 23 nonmalignant lymph node control specimens suggests that reactive, CD30+ B and T immunoblasts will not be confused with an HRS population by this technique. Putative B and T immunoblasts showed variable expression of CD30 and, consequently, did not form a discrete population as seen with HRS populations. Similar observations of immunoblasts have been made in paraffin tissue sections. 47 In addition, T immunoblasts would not express CD40, whereas B immunoblasts would express relatively strong CD19 and CD20, excluding these populations as putative HRS populations.
By FC, HRS cells generally had immunophenotypes similar to those seen in tissue sections. CD30, CD40, and CD95 were expressed uniformly, often brightly, when assessed in CHL by FC and currently represent the most useful antigens for the identification of HRS cells in lymph nodes involved by CHL. When evaluated by immunohistochemical analysis, CD30 3,39,40 and CD40 16, 17 also are expressed ubiquitously in CHL, whereas CD95 is expressed in greater than 90% of CHL cases. [21] [22] [23] [24] When evaluated by FC, the levels of expression of CD30 and CD95 on HRS cells usually were brighter than any other cell in the lymph node. In most cases, CD40 also was expressed most brightly on the HRS cells, although in occasional cases, nonneoplastic B cells showed similar levels of CD40 expression. CD15 expression was detected at some level (on the cell surface or in the cytoplasm) in 89% of cases, a finding in accord with the published literature on paraffin sections. 3, [40] [41] [42] Although not clearly separating HRS cells from benign cells in all cases, CD86 (present in 100% of cases, with 75% showing intermediate or brighter levels of expression) and HLA-DR (present in 88% of cases) were useful in diagnosing some cases of CHL; the corresponding percentages of cases expressing these 2 antigens in tissue sections are reported to be 100% 4,31,32 and 95% to 100%, 8, 34, 35 respectively.
The B cell-associated marker, CD20, was expressed in 35% of the cases evaluated by FC (usually weakly), similar to the results in paraffin sections of CHL. [48] [49] [50] Despite the preponderance of similarities between immunohistochemical analysis and flow cytometric evaluation of CHL, there were some differences between the levels of antigen expression measured by the 2 methods. Perhaps most interesting was the identification of some (usually lowlevel) CD45 expression on HRS cells by FC in 73% of the CHL cases after disruption of rosetting T cells, with 2 (13%) of 15 cases analyzed showing CD45 levels similar to those on mature B lymphocytes. Likewise, the L1236 cell line expresses intermediate CD45. Because HRS cells customarily are described as CD45-in most hematopathology texts, including the World Health Organization classification of hematolymphoid neoplasms, 3 we reviewed the immunohistochemical findings in 5 earlier cases of CHL (not evaluated by FC) containing sheet-like collections of HRS cells (the so-called syncytial variant of CHL) to evaluate CD45 expression within these collections in the absence of other intervening, CD45+ cells (lymphocytes, histiocytes, eosinophils, etc) that might obscure the true level of CD45 expression on the HRS cells. In all 5 cases, a minority of HRS cells clearly expressed weak CD45, and a small subset of HRS cells showed relatively strong expression of CD45 (unpublished observation). Taken together, these findings suggest that variable low-level CD45 expression is a feature of HRS cells.
A useful clue to the identity of the HRS cells of CHL is the phenomenon of T-cell rosetting around HRS cells. As shown by Sanders and coworkers, 38 unstimulated T cells spontaneously bind L428 cells though CD2-CD58 and LFA-1-CD54 interactions. In our study, L1236 cells also spontaneously bound to T cells from reactive lymph nodes and, similar to the findings of Sanders et al, 38 this binding was inhibited by a cocktail of antibodies to CD2, CD58, LFA-1, and CD54. In cell suspensions from lymph node biopsy specimens involved by CHL, the rosetting phenomenon also can be detected readily by FC, demonstrated by HRS cells with apparent expression of bright CD45 and CD3 or CD5 and increased FS. Moreover, these rosettes are disrupted readily by the blocking antibody cocktail, leading to loss of CD3 or CD5 (in most cases) and decreased CD45 and FS in association with the HRS cells. To our knowledge, T-cell rosetting of HRS cells has been described only in CHL, [8] [9] [10] [11] [12] 51 NLPHL, [51] [52] [53] and TCRLBCL, 53 suggesting that this phenomenon may be very useful in distinguishing these entities from other neoplasms. The importance of the individual macromolecules in the T cell-HRS cell interactions seemed to vary between patients because the individual blocking antibodies to CD2, CD58, LFA-1, and CD54 were differentially effective in disrupting T cell-HRS rosettes in different cases (Image 2).
The number of T cells bound to the HRS cells varied between cases (Image 6), a feature that can be estimated by FC. Unligated HRS cells do not have expression of CD3 or CD5, whereas T-cell rosettes have expression of T-cell antigens comparable to or greater than a small reactive T cell (Image 3). Ligated HRS cells with expression of CD3 or CD5 greater than a small T cell might be expected to have more than 1 T cell bound to an HRS cell, a conclusion supported by cell sorting experiments.
Case 6 demonstrates HRS rosettes with CD3 expression at or slightly greater than the level of a single T cell (Image 3B, top panel), corresponding to the majority of HRS cells that have 1 bound T cell and scattered cells having multiple bound T cells (Image 6A). In contrast, case 19 demonstrated rosettes with CD3 expression much greater than a single T cell (data not shown), corresponding to the multiple T cells bound to the HRS cell after cell sorting (Image 6D). Because preincubation with the blocking antibody cocktail decreased but did not result in the absence of apparent CD3 expression, we would predict that the sorted HRS cells of case 19 in the presence of blocking antibody cocktail still would demonstrate rosettes but with fewer attached T cells. Of note, initial flow cytometric studies of case 26 suggested that 34% of the HRS cells should have a bound T cell, yet no rosettes were observed morphologically after cell sorting (Image 6E). The reason for the absence of morphologically observed rosettes is not entirely clear, although the sorted HRS cells were somewhat degenerated (note the frayed cytoplasm of cells in Image 6E), and the T cells may have released from the HRS cells. Alternatively, multiple small bound T-cell membrane fragments (which cannot be detected by standard light microscopy) may result in significant apparent expression of CD3.
Our initial studies suggest that fibrosis of the lymph nodes involved by CHL is not an impediment to detecting HRS populations by FC. Cytopreparations (Cytospins) for morphologic evaluation of tissue suspensions of all clinical specimens are prepared routinely in our laboratory. For all cases for which the cytopreparation was reasonably cellular demonstrating more than 300 background lymphocytes (ie, the specimens were not degenerate), at least a few putative HRS cells were identified by cytomorphologic examination. Because most of our cases were of the nodular sclerosis subtype and because at least a few cases demonstrated dense fibrosis (fibrosis constituting at least 50% of the lymph node volume), extensive fibrosis of lymph nodes involved by CHL should not prevent the HRS cells from being suspended in solution and, consequently, being detected by FC.
The findings presented herein have important implications for the preparation of purified HRS cell populations. Currently, one of the most common methods of purifying HRS cells is to isolate individual cells by micromanipulation, 1 from cytocentrifuge preparations or from tissue blocks in which the cells of interest are immunostained (typically with CD30) to help in their identification. Likewise, most methods used to purify HRS cells from lymph node suspensions have selected CD30+ cells. 54, 55 It is important to note that HRS cells purified from cell suspensions in this manner would be contaminated by bound T cells and CD30+ cells that are not HRS cells (ie, immunoblasts). 54 As noted in Table 5 , the greatest purities were obtained in the presence of blocking antibodies (during flow cytometric analysis of purity, a fraction of the T cells "fell off" the HRS cell accounting for the lower purity of the unblocked cases). Note further that the purities of our 3-and 4-color sorting experiments performed in the presence of blocking antibodies are greater than those previously attributed to other purification methods. 54 Our data demonstrate that FC can directly identify the neoplastic HRS cells in lymph nodes involved by CHL. Our 10-color assay, which could be scaled down to 4-and 6-color assays, shows promise as an aid in diagnosing CHL and in purifying HRS cells for research. Examination of other antigens that may be useful in identifying HRS cells by FC is ongoing and may permit even greater sensitivity and specificity of the flow cytometric assay.
